Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect by Goos, Jeroen A. et al.






2020; 10(2): 567-584. doi: 10.7150/thno.36777 
Research Paper 
Delivery of polymeric nanostars for molecular imaging 
and endoradiotherapy through the enhanced 
permeability and retention (EPR) effect 
Jeroen A.C.M. Goos1,2, Andrew Cho3,4, Lukas M. Carter1, Thomas R. Dilling1, Maria Davydova1, Komal 
Mandleywala1, Simon Puttick5, Abhishek Gupta6, William S. Price6, John F. Quinn2, Michael R. Whittaker2, 
Jason S. Lewis1,7,8, Thomas P. Davis2,9 
1. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA. 
2. ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 
Australia.  
3. Department of Biochemistry & Structural Biology, Weill Cornell Graduate School, New York, USA. 
4. Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, USA.  
5. Probing Biosystems Future Science Platform, Commonwealth Scientific and Industrial Research Organisation, Herston, Australia. 
6. Nanoscale Organisation and Dynamics Group, Western Sydney University, Penrith, Australia. 
7. Department of Radiology, the Molecular Pharmacology Program and the Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering 
Cancer Center, New York, USA. 
8. Departments of Radiology and Pharmacology, Weill Cornell Medical College, New York, USA.  
9. Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, Australia.  
 Corresponding author: Prof. Dr. J.S. (Jason) Lewis, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA. +1 646 888 3038 
lewisj2@mskcc.org Prof. Dr. T.P. (Tom) Davis, Monash Institute of Pharmaceutical Sciences, Parkville Campus, Royal Parade, Melbourne VIC 3052, Australia. 
+61 3 99039260 thomas.p.davis@monash.edu 
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). 
See http://ivyspring.com/terms for full terms and conditions. 
Received: 2019.05.17; Accepted: 2019.10.04; Published: 2020.01.01 
Abstract 
Expression levels of biomarkers are generally unknown at initial diagnosis. The development of 
theranostic probes that do not rely on biomarker availability would expand therapy options for 
cancer patients, improve patient selection for nanomedicine and facilitate treatment of inoperable 
patients or patients with acquired therapy resistance. Herein, we report the development of star 
polymers, also known as nanostars, that allow for molecular imaging and/or endoradiotherapy based 
on passive targeting via the enhanced permeability and retention (EPR) effect.  
Methods: We synthesised a star copolymer, consisting of 7-8 centre-cross-linked arms that were 
modified with Gd3+ for magnetic resonance imaging (MRI), and functionalised either with 89Zr for in 
vivo quantification and positron emission tomography (PET) imaging, or with 177Lu for 
endoradiotherapy. 1H longitudinal relaxivities were determined over a continuum of magnetic field 
strengths ranging from 0.24 mT – 0.94 T at 37 °C (nuclear magnetic relaxation dispersion (NMRD) 
profile) and T1-weighted MRI contrast enhancement was visualized at 3 T and 7 T. PET imaging and 
ex vivo biodistribution studies were performed in mice bearing tumours with high EPR (CT26) or 
low EPR (BxPC3) characteristics. Therapy studies were performed in mice with high EPR tumours 
and mean absorbed organ doses were estimated for a standard human model.  
Results: The star copolymer with Gd3+ displayed a significantly superior contrast enhancement 
ability (T1 = 0.60 s) compared to the standard clinical contrast agent Gadovist (T1 = 1.0 s). 
Quantification of tumour accumulation using the radiolabelled nanostars in tumour-bearing mice 
demonstrated an exceptionally high uptake in tumours with high EPR characteristics (14.8 – 21.7 
%ID/g). Uptake of the star polymers in tumours with low EPR characteristics was significantly lower 
(P<0.001), suggesting passive tumour accumulation of the nanostars via the EPR effect. Survival of 









treated with lower therapy doses or control mice (P=0.001), demonstrating the utility of the 
177Lu-labelled star polymers as platforms for endoradiotherapy.  
Conclusion: Our work highlights the potential of star polymers as probes for the molecular 
imaging of cancer tissue or for the passive delivery of radionuclides for endoradiotherapy. Their high 
functionalisability and high tumour accumulation emphasises their versatility as powerful tools for 
nanomedicine. 
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Introduction 
Treatment of cancer patients with chemo- and 
radiotherapeutic agents is generally based on the 
expression of disease-specific biomarkers that 
represent cancer stage or disease progression. 
Moreover, with the emergence of personalised 
medicine, biomarker status at the tumour site has 
become increasingly important. Unfortunately, 
expression levels of biomarkers are usually unknown 
at initial diagnosis. For visualisation and 
quantification prior to treatment, molecular imaging 
probes are commonly based on pharmaceutical 
analogues of small molecules, peptides or antibodies 
that target prognostic or predictive biomarkers [1]. To 
assess biomarker status at the genomic level using 
genetic profiling techniques, the collection of tissue 
specimens via surgery or biopsy is generally required. 
Although minimally invasive profiling assays based 
on body fluid-derived specimens have been 
developed (i.e. liquid biopsies), they still suffer from 
low sensitivity and heterogeneous circulation levels of 
biomarkers, and translation towards clinical 
application is still in its early stages [2, 3]. The 
development of theranostic probes that do not rely on 
biomarker expression would expand therapy options 
for cancer patients in general and facilitate 
(neo)adjuvant treatment of inoperable patients. In 
addition, such probes may bypass the common 
clinical limitation of acquired resistance against 
biomarker-based therapies [4, 5]. 
To achieve accumulation of molecular imaging 
tracers or radiopharmaceuticals at the tumour site 
independent of biomarker expression, nanoparticles 
are the ideal platform. Nanoparticles can passively 
accumulate at the tumour site via the enhanced 
permeability and retention (EPR) effect often 
observed in solid tumours, which refers to the 
phenomenon of extensive angiogenesis, defective 
vascular architecture, impaired lymphatic drainage 
and increased expression of proteins associated with 
vascular permeability [6, 7]. In the preclinical setting, 
the EPR effect has been a widely accepted and proven 
strategy for the effective delivery of nanoparticles to 
the tumour site [8, 9]. Its utility in a clinical setting is 
still controversial due to the low overall median 
tumour accumulation of the current generation of 
nanoparticles [10]. Nevertheless, the majority of 
nanoparticles currently approved for clinical use (e.g. 
Doxil, Abraxane) rely on passive tumour targeting via 
the EPR effect [8, 10-12]. In addition to tumour model, 
nanoparticle type (organic vs. inorganic), shape 
(spherical, rod, other), size (hydrodynamic diameter < 
100 nm) and targeting strategy (active vs. passive) all 
contribute to the effectiveness of targeting the tumour 
and its microenvironment [10]. 
Polymeric star nanoparticles, also known as 
nanostars, are a class of macromolecules with a 
well-defined architecture of linear arms cross-linked 
at one end to form a central core. Due to their unique 
design and attractive chemical and physical 
properties, including their ease of synthesis, low 
viscosity, compact three-dimensional structure, high 
functionalisation potential and favourable biological 
characteristics, star polymers have attracted much 
interest in recent years as versatile platforms for 
theranostic applications [13, 14]. We have shown that 
star polymers could be synthesised via an ‘arm-first’ 
approach, using reversible addition-fragmentation 
chain-transfer (RAFT) polymerisation [15]. 
Functionalisation of the nanostars with 
gadolinium(III) (Gd3+) as a contrast agent for 
magnetic resonance imaging (MRI) significantly 
increased the water proton spin-lattice relaxation 
rates (R1), which in turn resulted in enhanced image 
contrast in T1-weighted MRI, thus demonstrating 
their potential as MRI contrast agents [16, 17]. In a 
one-pot synthesis with the radioisotope iodine-125 
(125I), we further showed that molecular imaging and 
nuclear medicine could be combined within a single 
nanostar [18]. To further emphasise their theranostic 
potential, we showed that the nanostars were 
effectively taken up by MCF-7 breast cancer cells for 
the endosomal delivery of doxorubicin [19]. 
In the current study we describe a star polymer 
in which amines are introduced as a functional handle 
for later modification with radionuclides, in addition 
to the Gd3+-functionalised monomer units also 
present in our previous star polymers. Relaxivity 
measurements at low magnetic field strengths 





demonstrate that the nanostars exhibit favourable 
paramagnetic properties, leading to increased 
longitudinal relaxivity and thus enhanced contrast in 
T1-weighted magnetic resonance images. At higher 
magnetic field strengths, the nanostars display a 
nearly two-fold increase in the T1-weighted image 
contrast compared to the clinical MRI contrast agent 
Gadovist. To quantify tumour uptake in in vivo 
tumour models, we functionalised the amines on the 
nanostars with chelators for radiolabelling. Nanostars 
radiolabelled with positron emitter zirconium-89 
(89Zr) demonstrate an exceptionally high 
accumulation at the tumour site, compared to other 
nanoparticles reported in the literature [10]. In a direct 
comparison, we show that nanostar accumulation in 
tumours with high vascular permeability is 
significantly higher than in tumours that exhibit less 
pronounced EPR characteristics, suggesting passive 
delivery of the nanostars to the tumour via the EPR 
effect. High tumour accumulation is confirmed using 
star polymers radiolabelled with beta emitter 
lutetium-177 (177Lu), and we demonstrate the high 
therapeutic potential of the nanostars.  
With regards to tumour accumulation, the star 
polymers compete with the top range nanoparticles 
published in current literature [9, 10]. Due to their 
demonstrated chemical and physiological versatility 
in the current study, the nanostars show great 
promise as platforms for theranostic applications. Not 
only would the star polymer scaffolds improve 
delivery of molecular imaging and 
(radio)pharmaceutical agents to tumour tissues 
independent of biomarker expression, but they also 
offer opportunities for novel imaging technologies, 
such as multimodal imaging, and machine learning 
[20, 21]. 
Results and Discussion 
Synthesis and Characterisation of the 
Nanostars 
Nanostars were produced using the arm-first 
approach via RAFT polymerisation (Figure 1) [13, 15]. 
First, linear polymer arms (4) were synthesised, 
consisting on average of 19× oligoethylene glycol 
methyl ether acrylate (OEGA) monomer units, 5× 
2-vinyl-4,4-dimethyl-5-oxazolone (VDM) monomer 
units and 4× Boc-protected aminoethyl acrylate 
(BAEA) monomer units, as confirmed by 1H NMR 
(Figure S1) [22, 23]. In general, a high poly(ethylene 
glycol) (PEG) content (9× PEG units per OEGA unit) 
leads to low toxicity of the nanoparticle, as well as a 
prolonged blood half-life due to its anti-fouling 
properties [24]. Azlactone-based monomer units 
(VDM) were introduced for functionalisation of the 
nanostars with DO3A-chelated Gd3+, which – due to 
its paramagnetic properties – enhances image contrast 
in MRI [25]. To allow for additional functionalisation 
of the nanostars, we introduced multiple Boc- 
protected amine moieties (BAEA) to the polymer 
arms. After Boc-deprotection of the amines, these 
functional groups could be conjugated to 
(radio)therapeutic agents using standard amine- 
reactive groups such as N-hydroxysuccinimide (NHS) 
esters or thiocyanates (SCN). To ensure that the 
pharmacokinetic properties of the nanostars were 
primarily dictated by the PEG component, the 
combined molecular weight fraction of VDM and 
BAEA monomer units was kept below 10% [26]. 
Polymer arms (MW = 9.5 kDa) were obtained with 
high purity (>99%) and good polydispersity index 
(PDI = 1.12) (Figures 2A and S1). Polymerisation 
kinetics indicated that VDM monomer was 
preferentially consumed over both OEGA and BAEA 
monomers (Figure S1), resulting in a decreasing 
gradient of VDM from the exterior of the polymer 
arms towards the interior. This gradient would 
benefit MRI contrast enhancement, since chelated 
Gd3+ atoms at the exterior of nanostars would be more 
readily accessible to exchanging water molecules [17]. 
The linear arms were then cross-linked at one end via 
chain extension with a difunctional crosslinking 
monomer (N,N′-methylenebis(acrylamide)), forming 
well-defined star polymer 6 (p(BAEA-co-OEGA- 
co-VDM); MW = 70.4 kDa, PDI = 1.16) with on average 
7 to 8 arms per nanostar, as calculated from the 
average molecular weight increase measured by gel 
permeation chromatography (GPC) in comparison to 
the average molecular weight of a single linear 
polymer arm (Figure 2A). Unreacted polymer arms 
were successfully removed by precipitation, yielding 
pure product 6 (>99%) with a hydrodynamic diameter 
(Dh) of 13 nm (Figures 2B and S2).  
The RAFT agent used for polymerisation was 
equipped with a trimethylsilyl-protected alkyne, 
offering additional functionalisation opportunities at 
the outer periphery of the nanostar using traditional 
alkyne-azide click chemistry [16]. To provide 
proof-of-concept, nanostar 6 was functionalised with 
fluorescent dye Fluor 488 (excitation wavelength = 
488 nm) on the RAFT agent. After removal of the 
trimethylsilyl protecting group, indicated by 
disappearance of its 1H NMR peak at δ = 0.06 ppm 
(Figure S3A), azide-functionalised Fluor 488 was 
conjugated to the alkyne on the RAFT agent via 
copper-click chemistry. GPC demonstrated that 
product with an excitation wavelength of 488 nm 
eluted at the expected elution time of the star 
polymer, suggesting that conjugation of the dye to the 
nanostar was successful (Figure S3B). 





Functionalisation of the nanostars with Fluor 488 
shows that the alkynes can be conjugated to 
chemically or physiologically active agents, such as 
fluorescent dyes or drugs like doxorubicin, 
emphasising the versatility of the nanostars as 
platforms for theranostics [19]. Since the 
alkyne-deprotection conditions used here are not 
optimal for the hydrolysis-sensitive VDM monomers, 
functionalisation of VDM is preferred prior to 
functionalisation of the alkynes. This experiment, 
however, provides proof-of-concept of the 
functionalisation potential of the RAFT agent. For 
simplicity, further experiments were performed using 
the trimethylsilyl-protected star polymers. 
Gd3+ was introduced to nanostar 6 by 
conjugating [Gd3+]DO3A to its VDM monomer units. 
To this end, 1-(5-amino-3-aza-2-oxypentyl)-4,7,10- 
tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclo
dodecane (DO3A-tBu-NH2) was acid-deprotected and 
loaded with Gd3+. Resulting product S4 
(2-aminoethyl-mono-amide-[Gd3+]DO3A) was 
reacted to the VDM monomer units in star polymer 6, 
followed by Boc-deprotection of the amine moieties 
under standard acidic conditions. The presence of 
Gd3+ in nanostar 7 (p(AEA-co-OEGA-co- 
[Gd3+]VDMD); Dh = 11 nm) led to considerable peak 
broadening in the 1H NMR spectrum, due to 
Gd3+-mediated shortening of T2 on nearby protons, 
suggesting successful conjugation (Figures 2C, S4 and 
S5). Inductively coupled plasma (ICP) spectrometry 
showed that star polymer 7 contained 10-11 Gd3+ 
atoms per molecule.  
Nanostars Enhance MRI Contrast by 
Shortening Water Proton T1 Relaxation Times 
To assess the ability of the nanostars to enhance 
MRI contrast, the magnetic properties of nanostar 7 
(p(AEA-co-OEGA-co-[Gd3+]VDMD) were measured at 
different magnetic field strengths. Its longitudinal 
relaxivity at lower field strengths (0.24 mT – 0.94 T; 
0.01 – 40 MHz) was measured by 1H NMR 
relaxometry, generating a nuclear magnetic resonance 
dispersion (NMRD) profile characteristic of a slowly 
reorienting Gd3+ complex (Figure 2D) [16, 27]. 
Maximal relaxivity at 37°C was 24.4 mM-1s-1 at 22.6 
MHz, which is higher than for our previously 
reported star polymers and, more importantly, over 
6-fold higher than reported for clinically used contrast 
agents such as Gadovist at similar field strength (3.7 
mM-1s-1 at 20 MHz) [16-19, 28-30].  
 
 
Figure 1. (A) Synthetic route of the star polymer (detailed reaction conditions are provided in the Methods section). (B) Schematic representation of theranostic 
star polymer synthesis. 






Figure 2. Characterization of the star polymers. (A) GPC traces of p(BAEA-co-OEGA-co-VDM) linear arm polymer (4; MW = 9.5 kDa, PDI = 1.12) and 
p(BAEA-co-OEGA-co-VDM) star polymer (6; MW = 70.4 kDa, PDI = 1.16). PDI: polydispersity index. (B) 1H NMR spectrum of p(BAEA-co-OEGA-co-VDM) star 
polymer (6) in CDCl3 (residual solvent peak indicated by *). (C) Size distribution profile of p(AEA-co-OEGA-co-[Gd3+]VDMD) star polymer (7; Dh =11 nm), as 
determined in triplo by dynamic light scattering (DLS). Dh: Number-average hydrodynamic diameter. (D) Model fitting of the nuclear magnetic relaxation dispersion 
(NMRD) profile of the nanostars obtained at 37°C. The best fit was obtained when using regular inner (IS) and outer (OS) sphere models under standard assumptions, 
extended to include the contributions from second sphere (SS) water molecules. The NMRD profile was characteristic for a slowly reorienting Gd3+ complex (max. 
relaxivity: 24.4 mM-1s-1 at 22.6 MHz). (E) Enhanced T1-weighted contrast was observed in BALB/c mice (n=3) carrying CT26 tumours, 3 days after the injection of 
nanostar 6 (p(BAEA-co-OEGA-co-VDM)) (tumour indicated by white arrow). PET images were obtained by co-injection of 89Zr-labelled nanostar 8 
(p([89Zr]Zr-DFO-AEA-co-OEGA-co-[Gd3+]VDMD)). 
 
The relaxivity of paramagnetic macromolecular 
nanostructures is defined by their molecular 
reorientation, water exchange and electronic 
relaxation properties [27, 31, 32]. Therefore, we 
characterised the paramagnetic properties of the 
nanostars by deducing standard relaxation 
parameters from the 1H NMRD profile at 310 K, 
including water residence time (τm), reorientational 
correlation time (τR) and electronic relaxation 
correlation time (τv). For quantitative assessment of 
these parameters, the 1H NMRD profile was fit using 
regular inner (Solomon–Bloembergen–Morgan) and 
outer (Hwang and Freed) sphere models under 
standard assumptions, extended to include 
contributions from second sphere water molecules 
(Figure 2D [31-38]. For estimation of the standard 
relaxation parameters, the following parameters were 
fixed during the fitting procedure: distance between 
the Gd3+ ion and the coordinated inner sphere water 
proton (rGd-H = 3.1 Å), number of inner sphere water 
molecules coordinated to Gd3+ (q = 1), water 
self-diffusion coefficient (D = 2.9 × 10-9 m2 s-1), distance 
of closest approach between Gd3+ ion and 
neighbouring outer sphere water proton (d = 3.6 Å), 
distance between Gd3+ ion and second sphere water 
proton (rss = 3.6 Å) and the hydration time of the 
second sphere water molecules (τss = 65 ps) [17, 39, 
40]. The parameters resulting from the most optimal 
fit are summarised in Table 1.  
 
Table 1. Molecular parameters of the nanostars obtained from 
the theoretical fitting of the NMRD data at 37 °C. 
Parameter Nanostar 
r1,max (mM-1s-1) 24.4 
τM (ns) 853 ± 43 
τR (ns) 3.9 ± 1.4 
τso (ps) 196 ± 11 
τv (ps) 42 ± 2 
qss 2.8 ± 0.2 
r1,max: maximal relaxivity, τM: water exchange rate, τR: reorientational correlation 
time, τso: electronic relaxation time at zero field, τv: electronic relaxation correlation 
time, qss: number of water molecules in second coordination sphere. 
 
 
The water residence time (τM = 853 ± 43 ns) was 
typical of a star polymer functionalised with 
amide-based Gd3+-complexing groups [16, 17]. As 
expected, the residence time of the water molecules 
coordinated to the nanostar was relatively high 
compared to their reported water residence times in 
the presence of clinically applied small molecule 
contrast agents [30]. A short water residence time 





implies fast water exchange and increased relaxivity, 
hence enhanced contrast on MR images, which is 
much easier to achieve for small molecules than for 
macromolecules. These data suggest that MRI 
contrast of the nanostars might be improved by 
increasing the water exchange rate of the nanostars, 
for example by adjusting the monomer ratios of the 
polymer arms [17]. Alternatively, substitution of the 
linker used to conjugate [Gd3+]DO3A to the nanostars 
by an amide-free analogue may result in a 2 to 8 times 
faster water exchange rate [41].  
The increased relaxivity of the nanostars at these 
field strengths compared to small molecule contrast 
agents is largely dictated by their long reorientational 
correlation time (τR = 3.9 ± 1.4 ns), which is several 
orders of magnitude higher than the reorientational 
correlation time of clinical contrast agents [30]. A long 
reorientational correlation time suggests restricted 
internal motion of the Gd3+ complex, which leads to 
enhanced MRI contrast, although it must be noted 
that the positive effect of the slower tumbling rate on 
the relaxivity tends to decrease with increasing field 
strengths [42].  
The electronic relaxation time at zero field 
strength (τso = 196 ± 11 ps) and electronic relaxation 
correlation time (τv = 42 ± 2 ps) were in the same range 
as electronic relaxation parameters previously 
reported for star polymers and were higher than those 
reported for most clinical small molecule contrast 
agents [17, 30]. At low magnetic field strengths, the 
effect of electronic relaxation contributes to the 
increased relaxivity of the nanostars compared to 
small molecule MRI contrast agents commonly used 
in the clinic [30].  
The paramagnetic properties of the star 
polymers were visualised at 3 T using a dilution series 
of the star polymer in HEPES buffer (pH 7.4). At 
higher concentrations, an increased spin-lattice 
relaxation rate (R1) was observed (Figure S6), 
resulting in significant T1-weighted contrast 
enhancement (Figure S7). Similarly, at 7 T, the 
nanostars significantly decreased the water proton T1 
relaxation time (T1 = 0.60 s) compared to that of the 
small molecule contrast agent Gadovist (T1 = 1.0 s) at 
equimolar Gd3+ concentrations, which denotes a T1 
shortening of 1.7× (Figure S7).  
To demonstrate the applicability of the nanostars 
as T1-weighted MRI contrast agents in vivo, MR 
images were acquired 3 days after the injection of 3 
mg or 10 mg of nanostar 6 
(p(BAEA-co-OEGA-co-VDM)) in mice (n = 3-5) 
engrafted with subcutaneous CT26 tumours. After the 
injection of 3 mg nanostar, some T1-weighted contrast 
enhancement was indeed observed in the tumour 
tissue (Figure S8A). After the injection of 10 mg 
nanostar, tumours could clearly be delineated due to 
the considerable contrast enhancement in the tumour, 
which was significantly higher than the tumour 
contrast prior injection (P = 0.013; Figures 2E and 
S8B). At this high dose (10 mg), however, some 
haematological toxicity was observed, leading to the 
death of one of the investigated mice. This toxicity 
was likely caused by the high concentration of 
nanostars accumulating in tissues that play an 
important role in red blood cell metabolism, such as 
liver and spleen, leading to a gradual – but lethal – 
decrease in red blood cell counts and haematocrit 
values (Figure S8C). Such toxic effects were not 
observed at a lower nanostar dose (3 mg) and, 
therefore, further evaluation of the optimal MR 
imaging dose is required.  
These data provide proof-of-concept that – after 
further dose optimization – the paramagnetic 
characteristics of the star polymers would allow for 
their application as T1 MRI contrast agents in a 
(pre)clinical setting.  
Nanostars Highly Accumulate in Tumours via 
EPR Effect 
To quantify tumour accumulation of the star 
polymers in tumour tissue, star polymer 7 
(p(AEA-co-OEGA-co-[Gd3+]VDMD) was 
functionalised with deferoxamine (DFO) for 
radiolabelling of the nanostars with 89Zr. Successful 
synthesis of star polymer p(DFO-AEA-co-OEGA- 
co-[Gd3+]VDMD) (Dh = 13 nm) was confirmed by the 
appearance of DFO-specific peaks at δ = 7.2 – 8.2 ppm 
in the 1H NMR spectrum (Figure S9). Radiolabelling 
of p(DFO-AEA-co-OEGA-co-[Gd3+]VDMD with 89Zr4+ 
was achieved with high radiochemical yield (>99%) 
and purity (>99%) and good molar activity (>290 
GBq/µmol) (Figure S10). In vitro stability assays 
demonstrated that the resulting star polymer 8 
(p([89Zr]Zr-DFO-AEA-co-OEGA-co-[Gd3+]VDMD)) 
was stable to decomposition in human serum over 
time (Figure S11). 
To demonstrate that uptake of the 89Zr-labelled 
nanostars was dominated by passive targeting via the 
EPR effect, tumour accumulation was compared 
between tumour models with highly leaky 
vasculature (CT26 colon cancer isografts; “high EPR”) 
and poorly leaky vasculature (BxPC3 pancreatic 
cancer xenografts; “low EPR”) [43]. Mice (n = 5) 
engrafted with subcutaneous CT26 or BxPC3 tumours 
were administered 10 MBq of nanostar 8 (MA = 64 
GBq/µmol). For visualisation of tumour 
accumulation, PET images were acquired 3 days after 
injection of the 89Zr-labelled nanostars (Figure 3A). 
The radiolabelled nanostars demonstrated a very 
clear delineation of tumours with high EPR 





characteristics (Figures 2E and 3B). Although 
peripheral tumour accumulation was also observed in 
tumours with low EPR characteristics, contrast 
relative to other tissues was less pronounced in low 
EPR tumours (Figure 3C).  
The high uptake in tumours with high EPR 
characteristics was confirmed by ex vivo 
biodistribution experiments, demonstrating a tumour 
accumulation of 14.8 ± 4.0 %ID/g after 3 days (Figure 
3D). Considerably lower tumour uptake values have 
been reported for the current generation of 
nanoparticles, emphasising the remarkably high 
tumour accumulation observed for the star polymers 
in this study [10]. This could be explained by the size, 
composition and flexibility of the nanostars [44, 45]. 
First, the large size of the nanostars prevents their 
renal clearance, but enables their accumulation at the 
tumour site through the leaky vasculature associated 
with the EPR effect. Second, the primary component 
of the nanostars is PEG, which extends their blood 
circulation time and, as such, prolongs their exposure 
to the tumour. Third, the stereochemical flexibility of 
the nanostars facilitates their deep penetration into 
the tumour tissue, contributing to the high uptake 
levels at the tumour site. Higher tumour uptake 
values for passively targeting nanoparticles have only 
been reported for a few inorganic and fewer organic 
nanoparticles [9, 10]. However, inconveniently high 
liver and spleen uptake values were also reported for 
those nanoparticles, in most cases significantly higher 
than the tumour uptake values [9]. In the current 
study, the non-target organ with the highest 
concentration of 89Zr-labelled nanostars was the 
spleen, with an uptake value that was similar to 
uptake in the tumour (17.7 ± 3.7 %ID/g). Besides 
accumulation of the nanostars in the blood circulation 
(8.4 ± 1.3 %ID/g), all other organs displayed uptake 
values of less than 5.5 %ID/g. 
The peripheral tumour accumulation observed 
in the BxPC3 xenografts highlights the poor 
penetration of the 89Zr-labelled nanostars into the low 
EPR tumours (Figure 3C). That is, pancreatic tumours 
are notorious for their dense extracellular matrix, 
restricting penetration of (nano)therapeutic agents in 
general [46, 47]. Uptake differences between low and 
high EPR tumours were quantified by comparing the 
maximal uptake values in three-dimensional volumes 
of interest (VOIs) obtained from the PET images of the 
low and high EPR tumour models (Figure 3E). 
Evidently, nanostar uptake values in tumours with 
high EPR characteristics were significantly higher 
than in tumours with low EPR characteristics 
(P<0.001), suggesting that uptake of the nanostars in 
tumour tissue is mainly dictated by passive 
accumulation via the EPR effect. 
 Although the EPR effect has been a mainstay 
delivery strategy for nanoparticles in the preclinical 
setting, its clinical utility remains debated [8]. 
Clinically approved nanoparticles that rely on passive 
tumour targeting have only shown limited efficacy 
due to heterogeneity across patients and cancer types, 
which has contributed to the questionable reputation 
of nanoparticles in clinic [8]. To account for the 
apparent heterogeneity and to expand our 
understanding of the EPR effect in human cancers, 
molecular imaging agents that can quantify and 
visualise the EPR effect in patients are needed. The 
radiolabelled nanostars may benefit cancer imaging 
and treatment by selecting patients for nanomedicine 
that demonstrate enhanced permeability and 
retention of the nanostars, with the aim to increase the 
efficacy of currently approved nanotherapeutics. The 
combination of a paramagnetic component (Gd3+) and 
a radionuclide (89Zr4+) within a single nanoparticle 
would also allow for multimodal imaging, for 
example using emerging hybrid imaging techniques 
such as simultaneous PET/MRI imaging, as well as 
facilitate the spatial co-registration of multimodal 
images in machine learning [8, 48]. Additionally, the 
high accumulation of the nanostars in high EPR 
tumours suggest that they could be used as platforms 
for the treatment of solid tumours with leaky 
vasculature, after their functionalisation with 
(radio)therapeutic agents, for example when patients 
appear inoperable due to an unfavourable anatomical 
location of the tumour or when patients have become 
resistant to standard antibody-based therapies [19, 
49]. 
Endoradiotherapy with Nanostars Leads to 
Prolonged Survival 
To assess the endoradiotherapeutic potential of 
the nanostars, star polymer 7 (p(AEA-co-OEGA-co- 
[Gd3+]VDMD) was functionalised with trans- 
cyclooctene (TCO) to enable radiolabelling of the 
nanostars with a 177Lu-labelled DOTA-functionalised 
tetrazine (Tz). We have previously used a similar 
two-step approach for the radiolabelling of 
monoclonal antibodies with actinium-225 (225Ac) [50]. 
Here, this labeling approach was chosen to prevent 
metal exchange of Gd3+ and 177Lu3+ during the 
radiolabelling procedure, which are both complexed 
by a structurally similar chelator (DO3A and DOTA, 
respectively). Successful synthesis of star polymer 9 
(p(TCO-AEA-co-OEGA-co-[Gd3+]VDMD); Dh = 12 nm) 
was confirmed by the appearance of TCO-specific 
peaks at δ = 5.5 ppm and δ = 1.0 – 2.0 ppm in the 1H 
NMR spectrum (Figure S12). Tetrazine-poly(ethylene 
glycol)7-DOTA (10, Tz-PEG7-DOTA) was 
radiolabelled with 177Lu3+ and reacted to star polymer 





9 to obtain star polymer 11 (p([177Lu]Lu-DPAEA- 
co-OEGA-co-[Gd3+]VDMD)) with high radiochemical 
yield (87%) and purity (>99%) and high molar activity 
(615 GBq/µmol) (Figure S13). 
 
 
Figure 3. In vivo quantification and positron emission tomography (PET) imaging of 89Zr-labelled nanostar 8 (p([89Zr]Zr-DFO-AEA-co-OEGA-co-[Gd3+]VDMD)). (A) 
Uptake study scheme of 89Zr-labelled nanostars in BALB/c mice, isografted with CT26 colon cancer (high EPR) or xenografted with BxPC3 pancreatic cancer (low 
EPR) cells. (B-C) Representative coronal and maximum intensity projection (MIP) PET images of BALB/c mice (n=5 per study) carrying CT26 or BxPC3 tumours, 3 
days after injection of 89Zr-labelled nanostars (~10 MBq, MA = 64 GBq/µmol). High accumulation of the 89Zr-labelled nanostars was observed in CT26 isografts, 
whereas low and mainly peripheral accumulation was observed in BxPC3 xenografts, indicating passive tumour uptake via the EPR effect. Scale bars are in %ID/g. (D) 
Biodistribution profile 3 days after injection of 89Zr-labelled nanostars in BALB/c mice isografted with CT26 colon cancer cells. Highest accumulation was observed 
in tumour tissue and spleen. S.I.: small intestine, L.I.: large intestine. (E) Comparison of maximum uptake values in volumes of interest (VOIs) of CT26 and BxPC3 
tumours. Uptake of 89Zr-labelled in CT26 (high EPR) isografts was significantly higher than uptake in BxPC3 (low EPR) xenografts, as determined by the 
independent-samples t-test (P=0.001). 






Figure 4. In vivo quantification of 177Lu-labelled nanostar 11 (p([177Lu]Lu-DPAEA-co-OEGA-co-[Gd3+]VDMD)). (A) Uptake study scheme of 177Lu-labelled nanostars 
in BALB/c mice, isografted with CT26 colon cancer cells. (B) Biodistribution profile of 177Lu-labelled nanostars (~0.8 MBq, MA = ~5 GBq/µmol) up to 3 days after 
injection in BALB/c mice isografted with CT26 colon cancer cells. Highest tumour accumulation was observed after 3 days, as well as accumulation in liver and spleen. 
S.I.: small intestine, L.I.: large intestine. 
 
The activity distribution of the 177Lu-labelled 
nanostars was measured in mice (n = 4 per timepoint), 
bearing subcutaneous CT26 isografts (i.e. high EPR 
tumours). Biodistribution profiles were obtained at 
different time points after the injection of 0.8 MBq of 
nanostar 11 (MA = 5 GBq/µmol) (Figure 4A). The 
biodistribution profile of the 177Lu-labelled nanostars 
after 3 days demonstrated a remarkably high uptake 
in tumour tissue (21.7 ± 8.4 %ID/g) (Figure 4B), which 
was even higher than the observed uptake of the 
89Zr-labelled nanostars (Figure 3D).  
 These data confirmed the clearance of the 
nanostars from the blood majorly via liver and spleen, 
after an apparent partial initial clearance via the 
kidneys. Although the high splenic uptake (35.3 ± 4.2 
%ID/g) was observed for the 89Zr-labelled nanostars 
as well, the 177Lu-labelled nanostars also displayed 
high accumulation in liver tissue (42.0 ± 4.7 %ID/g). 
This discrepancy may be explained by changes in 
molecular weight or surface charge of the star 
polymers after reaction with [177Lu]Lu-Tz-PEG7- 
DOTA, rather than accumulation of detached 
[177Lu]Lu-Tz-PEG7-DOTA or free 177Lu3+ after 
demetallation from the DOTA chelators. That is, 
clearance of unbound [177Lu]Lu-Tz-PEG7-DOTA is 
likely to proceed via the urinary tract instead of the 
hepatobiliary tract and free 177Lu3+ tends to 
accumulate in bone [51]. Except for accumulation in 
the blood (7.5 ± 1.8 %ID/g), uptake of the 
177Lu-labelled nanostars in all other organs was less 
than 5.0 %ID/g.  
Accumulation of the 177Lu-labelled nanostars in 
tumour tissue seemed to decrease after 3 days (Figure 
S14), possibly implying washout of the nanostars 
from the tumour over time. More likely, however, the 
seemingly rapid decrease of tumour accumulation at 
later time points is an artefact of the tumour model 
used in this study. Namely, the impaired angiogenesis 
and leaky vasculature of CT26 tumours is inherently 
caused by rapid growth of the tumour mass [6, 43]. In 
general, for a fair comparison of activity 
concentrations between tissues, tissue mass and 
tissue-to-tissue ratios are assumed to remain 
reasonably consistent over time. In the fast-growing 
tumour model applied here, however, the tumour 
mass increased six- to eight-fold over the course of the 
14-day 177Lu-therapy study (Figure S15A), causing a 
rapid decrease in uptake values per tumour mass at 
later time points. Ignoring the weight component 
from the biodistribution calculations by analysing 
tumour uptake in %ID instead of %ID/g (Figure 
S15B), a much less pronounced washout effect is 
observed, as is indicated by the shallower slope of the 
uptake curve in %ID after 3 days. These data suggest 
that the measured tumour uptake values at 7 days 
and 14 days are an underestimation of the actual 
nanostar uptake and retention in the tumour, 
compared to the clinical situation in which tumour 
growth is generally slower. 
 






Figure 5. Therapy studies with 177Lu-labelled nanostars in BALB/c mice isografted with CT26 colon cancer cells. Mice were treated with 1.5 MBq, 3.7 MBq or 7.4 
MBq of p([177Lu]Lu-DPAEA-co-OEGA-co-[Gd3+]VDMD) star polymer (11). Mice in the two control groups were injected either with vehicle (0.9% sterile saline) or 
non-radioactive nanostar 6 (p(BAEA-co-OEGA-co-VDM); 23 µg per mouse). (A) Tumour volumes increased rapidly for mice in the two control groups and the low 
dose therapy cohort (1.5 MBq). Tumour volumes increased considerably slower for mice treated with medium (3.7 MBq) and high doses (7.4 MBq). (B) The 
cumulative survival of mice in each cohort increased significantly with increasing therapy dose, demonstrating the therapeutic potential of the 177Lu-labelled nanostars. 
The haematological toxicity of treatment with 177Lu-labelled nanostars was assessed by measuring alterations in (C) red blood cell counts, (D) haematocrit values, (E) 
platelet counts, and (F) white blood cell counts. Further, systemic toxicity was monitored by measuring signs of lethargy, loss of appetite and (G) body weight. 
 
 Based on the full biodistribution data of the 
177Lu-labelled nanostars (0-14 days), mean absorbed 
organ doses in mice were calculated, as well as the 
therapeutic index per organ, which is defined as the 
ratio of the radiation-absorbed dose in the tumour 
divided by the dose in a (radiosensitive) tissue (Table 
2) [52]. Mean absorbed organ doses in mice were 
calculated based on trapezoidal integration of the 
time-activity curves obtained from the biodistribution 
data (Figure S16) and demonstrated low to moderate 
therapeutic indices for half of the investigated organs. 
It must be noted, however, that the values displayed 
in Table 2 are likely an underestimation of the actual 
therapeutic indices, since tumour uptake values are 
based on time-activity curves generated from a 
fast-growing tumour model, which gives an artificial 
decrease of 177Lu-labelled nanostar accumulation at 
later time points.  
 
Table 2. Murine organ-level absorbed dose coefficients and 
therapeutic indices calculated from the biodistribution data of the 
177Lu-labelled nanostars. 
Organ Absorbed dose (Gy/MBq) Therapeutic index 
Tumour 1.94 - 
Blood 1.63 1.19 
Brain 0.04 41.23 
Lungs 0.85 2.27 
Liver 6.87 0.28 
Spleen 4.55 0.43 
Pancreas 0.32 6.09 
Stomach 0.22 8.86 
Intestines 0.14 13.89 
Kidneys 0.78 2.47 
Bone  0.34 5.72 





Based on the dosimetry data, maximal 
administered activities for the therapy study were 
guided by normal organ radiation absorbed dose 
tolerances, leading to selection of the following 
activities for preclinical dose escalation studies: 1.5 
MBq (40 µCi), 3.7 MBq (100 µCi) and 7.4 MBq (200 
µCi) [52, 53]. The majority of nanoparticle-based 
therapies, as well as most antibody-based therapies, 
rely on clearance of the (radio)therapeutic agent via 
regular clearance organs, including the liver and 
spleen. Indeed, those organs typically demonstrate 
high uptake of the (radio)therapeutic agents, 
however, they can also tolerate relatively high 
absorbed doses (>3000 cGy for liver, >1500 cGy for 
spleen) [51, 53]. Commonly, the dose-limiting tissue 
for radionuclide therapy is the red marrow, which has 
a maximum tolerated dose of approximately 150 cGy 
[52]. At a therapeutic administered activity of 3.7 
MBq, the estimated absorbed doses to liver, spleen 
and bone would be 2540 cGy, 1680 cGy and 125 cGy, 
respectively (Table S1), which are close to or below 
the maximum tolerated doses for these organs. 
Therefore, mice bearing subcutaneous CT26 isografts 
(i.e. high EPR tumours) were injected with low dose 
(1.5 MBq), medium dose (3.7 MBq) or high dose (7.4 
MBq) of p([177Lu]Lu-DPAEA-co-OEGA-co- 
[Gd3+]VDMD) star polymer (11), after their 
randomization into five cohorts (n = 8 per cohort) 
with approximately equal tumour volume 
distributions. Mice in the control groups were injected 
either with vehicle (0.9% sterile saline) or 
non-radioactive nanostar 6 (p(BAEA-co-OEGA-co- 
VDM). The two mice with the smallest and largest 
tumours were excluded from each cohort to minimize 
bias due to outliers, effectively resulting in n = 6 mice 
per cohort. Notably, tumour growth was considerably 
impaired with increasing therapy doses (Figure 5A). 
No significant differences in mean tumour volume 
were observed between the control cohorts and the 
low therapy dose (1.5 MBq) cohort. Consequently, 
mice treated with the high dose of 177Lu-labelled 
nanostar (7.4 MBq; median survival = 35 days) 
demonstrated a significantly prolonged survival (P = 
0.001) compared to mice treated with the medium 
therapy dose (3.7 MBq; median survival = 24 days), 
mice treated with the low therapy dose (1.5 MBq; 
median survival = 17 days) and mice in the control 
groups (median survival = 14 days for both groups) 
(Figure 5B). Haematoanalysis (n = 3 per cohort) 
demonstrated a marked decrease in white blood cell 
counts for all mice treated with the 177Lu-labelled 
nanostars (Figures 5C-F). For mice in the low therapy 
dose (1.5 MBq) cohort, white blood cell counts 
recovered to their initial levels within one week. Mice 
in the medium (3.7 MBq) and high (7.4 MBq) therapy 
cohorts recovered their original white blood cell 
values approximately 28 days after injection. Such 
decreases in white blood cell values are not 
uncommon for endoradiotherapeutic approaches and 
are generally counteracted in the clinical setting by 
the administration of Granulocyte Colony Stimulating 
Factor (G-CSF) [54, 55]. No significant alterations 
were observed for the other blood markers, nor did 
the mice show any outward signs of toxicity, such as 
lethargy, loss of appetite or decreasing body weight 
(Figure 5G). In view of these results, 
endoradiotherapy with 177Lu-labelled nanostars is a 
promising novel treatment strategy for patients with 
tumours with demonstrated EPR characteristics. 
 
 
Figure 6. Absorbed dose estimations for the ICRP89 adult male model, calculated from biodistribution data of the 177Lu-labelled nanostars in BALB/c mice isografted 
with CT26 colon cancer cells. Absorbed doses are estimated for administered theoretical doses of 5.0 GBq and 7.4 GBq. Maximum tolerated doses are indicated for 
liver (blue), spleen (green) and red marrow (red). 





To translate dosimetry predictions from mouse 
to human, mean absorbed organ doses were 
estimated for the ICRP89 adult male model within the 
FDA-approved dosimetry software OLINDA 2.0 
(Figure 6 and Table S2) [56]. In clinical trials with 
177Lu-labelled monoclonal antibodies, patients are 
generally administered radioactive doses of ~7.4 GBq 
(200 mCi) [51]. At this dose, the 177Lu-labelled 
nanostars would deliver an estimated dose to red 
marrow (1.55 Gy) and spleen (13.10 Gy) close to their 
maximum tolerated dose (1.5 Gy and 15 Gy, 
respectively). As it is difficult to accurately predict 
therapeutic response in humans from mouse data, 
optimisation may be needed to determine at which 
dose the 177Lu-labelled nanostars would demonstrate 
maximal therapeutic effect with minimal toxicity. 
Potentially, fractionated administration of lower 
single doses of 177Lu-labelled nanostar would increase 
efficacy without significant side-effects [57]. 
Conclusions 
In the current study, we developed star 
polymers in which multimodality molecular imaging 
is combined with endoradiotherapy, demonstrating 
the versatility of nanostars as platforms for 
theranostics. The star polymers were synthesised via 
‘arm-first’ RAFT polymerisation with good 
polydispersity index and high functionalisation 
potential, due to the introduction of easily 
functionalisable amine moieties to the polymer arms 
and the addition of a functionalisable alkyne at the 
end of each arm. The presence of Gd3+ in the polymer 
arms led to a more than six-fold improvement of the 
relaxivity at lower magnetic field strengths, compared 
to the clinically used contrast agent Gadovist, and 
demonstrated an almost two-fold enhancement of 
T1-weighted image contrast at higher, clinically 
relevant magnetic field strengths. Functionalisation of 
the amines with [89Zr]Zr-DFO showed that the 
nanostars accumulated remarkably well in tumours 
with established EPR properties and significantly less 
in tumours with less pronounced EPR characteristics, 
which was confirmed by measuring the tumour 
uptake of [177Lu]Lu-DOTA-functionalised star 
polymers. The high tumour accumulation of the 
nanostars (14.8 – 21.7 %ID/g) in tumours with high 
EPR characteristics suggested that the nanostars are 
passively taken up in tumour tissue via the EPR effect. 
Moreover, tumour uptake of the nanostars was much 
higher than has been reported for the majority of 
nanoparticles elsewhere. The endoradiotherapeutic 
potential of the nanostars was demonstrated in mice 
and extrapolated from the mouse experiments to a 
human model, estimating that at standard injected 
doses, the doses to radiosensitive off-target organs 
would be lower than (i.e. liver, spleen) or close to (i.e. 
red marrow) the maximum tolerated doses for those 
organs.  
Our work highlights the potential of nanostars as 
probes for molecular cancer imaging or for the passive 
delivery of radionuclides for endoradiotherapy. Their 
high accumulation in tumours with leaky vasculature 
may aid in selecting patients that will benefit from 
standard clinical nanomedicine treatments, which 
currently seem to suffer from low efficacy due to 
heterogeneity between patients and cancer types. 
Furthermore, the nanostars may offer opportunities 
for the palliative treatment of cancer patients, for 
example when patients appear inoperable due to 
irresectability of the tumour or when antibody-based 
therapies are failing due to acquired resistance. As 
such, this study emphasises the versatility of the 




Chemicals and anhydrous solvents were 
purchased from Sigma-Aldrich (Saint Louis, USA), 
dichloromethane and diethyl ether from 
Chem-Supply (Gillman, Australia), acryloyl chloride 
and all other solvents from Merck (Darmstadt, 
Germany). 2-Aminoethyl-mono-amide-DO3A-tris(t- 
Bu ester) and 1-(4-isothiocyanatophenyl)-3-(6,17- 
dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxyla
mino)-6,11,17,22-tetraazaheptacosane) thiourea (SCN- 
Bn-DFO) were obtained from Macrocyclics (Plano, 
USA) and Chelex® 100 resin from Bio-Rad (Hercules, 
USA). (E)-Cyclooct-4-enyl 2,5-dioxo-1-pyrrolidinyl 
carbonate (TCO-NHS ester) was purchased from 
Click Chemistry Tools (Scottsdale, USA). 2-Vinyl- 
4,4-dimethyl-5-oxazolone (VDM) was kindly 
provided for by Prof. L. Fontaine (University of 
Maine, Le Mans, France) and 2,2',2''-(10-(2-(tetrazine- 
poly(ethyleneglycol)7-amino)-2-oxoethyl)-1,4,7,10- 
tetraazacyclododecane-1,4,7,10-tetraacetic acid (Tz- 
PEG7-DOTA) by Dr. S. Poty (MSKCC, New York, 
USA). Synthesis of RAFT agent 3-(trimethylsilyl)prop- 
2-yn-1-yl 2-((((3-propionic acid)thio)carbonothioyl) 
thio)propanoate) (TSPPA) has been described 
previously [16]. [Gd3+]2,2',2''-(10-(2-((2-aminoethyl) 
amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,
4,7-triyl)triacetic acid (2-aminoethyl-mono-amide- 
[Gd3+]DO3A) was synthesised according to our 
previously described methods [28]. All chemicals 
were used without further purification, unless 
otherwise specified. Azobis(isobutyronitrile) (AIBN) 
was recrystallised from methanol before use. 
Polymers were dialysed using Cellu-Sep 





regenerated cellulose tubular membranes with 
nominal molecular cut-off weights of 3500 or 12 000–
14 000 Da. 
Zirconium-89 (89Zr) was produced via proton 
beam bombardment of yttrium foil and isolated as 
high purity [89Zr]Zr-oxalate [58]. Lutetium-177 (177Lu) 
was purchased from Oak Ridge National Laboratory 
(Oak Ridge, USA) as [177Lu]LuCl3 in 0.1M HCl. 
Characterisations 
A Grace Reveleris® X2 flash system with silica 
packed cartridges was used for flash column 
chromatography.  
Instant thin-layer chromatography (iTLC) was 
performed using silica-impregnated glass microfiber 
paper (Agilent, Santa Clara, USA) in 0.1M sodium 
citrate buffer (pH5), unless otherwise stated, and 
analysed using a BIOSCAN AR 2000. 
NMR spectra were measured on a Bruker 
Avance III 400 MHz (400.13 MHz, 9.4 T) spectrometer 
at room temperature (Bruker Topspin, v1.3). The 
residual solvent peak was used as a reference to 
determine chemical shifts (δ) (7.27 ppm for CDCl3, 
4.79 ppm for D2O, 2.50 ppm for DMSO-d6). Coupling 
constant (J) and multiplicity (singlet s, doublet d, 
triplet t, quartet q, multiplet m) were described where 
possible.  
A Shimadzu modular system equipped with a 
SIL20AD automatic injector, a DGU12A degasser, a 
CTO10A column oven (40 °C), a LC10AT pump, a 
RID10A differential refractive-index detector and a 
SPD10A Shimadzu UV/Vis detector was used for gel 
permeation chromatography (GPC) Polymer 
Laboratories, Cirrus v2.0). Samples were measured in 
N,N′-dimethylacetamide (HPLC grade, 0.03% w/v 
LiBr, 1 mL min−1), filtered before use (cut-off: 0.45 μm) 
and ran through a 50 × 7.8 mm guard column (bead 
size: 5 μm) followed by three KF-805L columns in 
series (300 × 8 mm linear columns, bead size: 10 μm, 
pore size maximum: 5000 Å). Linear poly(styrene) 
standards (0.5–2000 kDa, Polymer Laboratories) were 
used for calibration.  
Dynamic light scattering (DLS) was performed 
on a Malvern Zetasizer Nano Series equipped with a 4 
mW He-Ne laser (λ = 633 nm) and an avalanche 
photodiode detector (detection angle 173°). 
Gadolinium (Gd3+) levels (2.0-5.0 mg/ml) were 
measured by inductively coupled plasma–optical 
emission spectrometry (ICP-OES) on an OPTIMA 
7300 (Western Sydney University, Sydney, Australia) 
or OPTIMA 7000DV (Hunter College, New York, 
USA) spectrometer (Perkin Elmer) or by inductively 
coupled plasma mass spectrometry (ICP-MS) on a 
Perkin Elmer NexION 300X ICP-MS (University of 
Missouri, Columbia, USA) using standard operating 
procedures. Calibration was performed using a five- 
or six-point calibration curve based on Gd3+ standards 
obtained from Sigma-Aldrich (Saint Louis, USA).  
An Agilent 1260 Infinity system equipped with 
an autosampler (G1367E), binary pump (G1312C), 
DAD module (G4212A) and an 1100 MSD mass 
spectrometer, using LC/MSD Chemstation 
Rev.B.04.03 and Masshunter Easy Access Software 
were used for ultra-high performance liquid 
chromatography - mass spectroscopy (LC-MS). For 
mass spectroscopy, a quadrupole atmospheric 
pressure ionisation - electrospray (API-ES) source was 
used with a capillary voltage of 3000 V and a drying 
gas temperature of 350 °C. For reverse-phase 
high-performance liquid chromatography (HPLC), a 
Poroshell 120 EC-C18 column (3.0 × 50 mm, 2.7 μm) 
was used at 35 °C (injection volume 1 μl; 0.1% formic 
acid in water, followed by an increasing gradient of 
5-100% of 0.1% formic acid in acetonitrile over 3.8 
minutes; flow rate 0.500 mL/min).  
Radioactive samples were counted using a 2480 
Wizard2 automatic gamma counter (1 minute per 
measurement; 800-1000 keV for 89Zr, 40-300 keV for 
177Lu). 
Synthesis and Characterisation of Nanostars 
Linear polymer arm 4 (p(BAEA-co-OEGA-co- 
VDM)) was synthesised by dissolving Boc-protected 
aminoethyl acrylate (BAEA; S2; 5 eq; 1.00 g, 4.65 
mmol), poly(ethylene glycol) methyl ether acrylate 
(OEGA480; 2; 25 eq; 11.1 g, 23.2 mmol), 
2-vinyl-4,4-dimethyl-5-oxazolone (VDM; 3; 5 eq; 0.647 
g, 4.65 mmol), 3-(trimethylsilyl)prop-2-yn-1-yl-2- 
(((((3-propionic acid)thio)carbonothioyl)thio) 
propanoate) (TSPPA; 1; 1 eq; 0.339 g, 0.929 mmol) and 
2,2-azobis(2-methylpropionitrile) (AIBN; 0.1 eq; 
1.52×10-2 g, 9.29×10-2 mmol) in 30.2 mL methanol, 
followed by purging with nitrogen gas at 0°C for 1 
hour. The reaction mixture was heated to 70°C and 
stirred for 7.5 hours under nitrogen atmosphere. The 
polymerisation was halted by rapidly cooling the 
reaction mixture to 0°C and exposing it to air. 
Impurities were removed by three precipitation cycles 
in 50% diethyl ether in petroleum benzine (BR 
40-60°C). Purified product 4 (yellow oil, 7.68 g) was 
dried using an air flow and analysed by GPC and 1H 
NMR (CDCl3). 
Cross-linked star polymer 6 (p(BAEA-co-OEGA- 
co-VDM)) was formed by stirring a solution of 
N,N′-methylenebis(acrylamide) (5; 8 eq; 664.8 mg, 4.3 
mmol), AIBN (0.33 eq; 29.5 mg, 0.18 mmol) and 4 (1 
eq; 5.39×103 mg, 0.54 mmol) in 60 mL toluene under 
nitrogen atmosphere at 70°C for 24 hours, after 
purging the reaction mixture with nitrogen gas at 0°C 
for 1 hour. The reaction was terminated by rapidly 





cooling the reaction mixture to 0°C and exposing it to 
air. Impurities were removed by three precipitation 
cycles in 1/10 (v/v) chloroform/diethyl ether. 
Purified product 6 (yellow oil, 2.37×103 mg) was dried 
using an air flow and analysed by 1H NMR (CDCl3), 
GPC and DLS. 
Gadolinium(III)-functionalised star polymer 7 
(p(AEA-co-OEGA-co-[Gd3+]VDMD)) was synthesised 
by stirring triethylamine (8 arms × 5 VDM × 1.5 eq; 
0.283 mL, 2.0 mmol), S4 (8 arms × 5 VDM × 1.5 eq; 
1.22×103 mg, 2.0 mmol) and 6 (1 eq; 2.37×103 mg, 0.034 
mmol) in 5.8 mL DMF for 48 hours. After removing all 
solvent and triethylamine in vacuo, a large excess of 
85% phosphoric acid solution was added and the 
reaction mixture was stirred for 30 minutes. Purified 
product 7 (1.42×103 mg) was obtained after dialysis in 
water and was stored in solution at 4°C. The product 
was characterised by 1H NMR (CDCl3), DLS and 
ICP-OES or ICP-MS.  
Radiolabeling of Nanostars with 89Zr 
Star polymers were functionalised with 
deferoxamine (DFO) by mixing p(AEA-co-OEGA-co- 
[Gd3+]VDMD) (7; 1 eq; 55 mg, 6.5×10-4 mmol) in 5 mL 
0.1M NaHCO3 (pH 9) with SCN-Bn-DFO (10 eq; 5 mg, 
6.5×10-3 mmol) in 50 µL DMSO at 40°C for 16 hours. 
Small molecular weight impurities were removed by 
dialysis in water and large molecular weight 
impurities using PTFE syringe filters (0.1 µm, GE 
Healthcare). Purified p(DFO-AEA-co-OEGA-co- 
[Gd3+]VDMD) star polymer (53.1 mg) was stored in 
solution at 4°C until further use and analysed by 1H 
NMR (DMSO-d6) and DLS. 
[89Zr]Zr-oxalate (~90 MBq) was neutralised 
using 1M Na2CO3 and subsequently mixed with 
p(DFO-AEA-co-OEGA-co-[Gd3+]VDMD) star polymer 
(120 µg) in 360 µL 0.1M HEPES buffer (pH 7.4). 
Desired product p([89Zr]Zr-DFO-AEA-co-OEGA-co- 
[Gd3+]VDMD) star polymer (8) was obtained after 30 
minutes incubation at 37°C and used without further 
purification. Radiochemical purity was measured by 
iTLC. In vitro stability of star polymer 8 
(p([89Zr]Zr-DFO-AEA-co-OEGA-co-[Gd3+]VDMD)) 
with respect to radiochemical purity and 
demetallation was assessed after overnight incubation 
of the nanostar in saline, PBS and human AB-type 
serum at 37°C (n = 3). 
Radiolabeling of Nanostars with 177Lu 
Star polymers were functionalised with trans- 
cyclooctene (TCO) by stirring p(AEA-co-OEGA-co- 
[Gd3+]VDMD) (7, 1 eq; 95 mg, 1.1×10-3 mmol) in the 
presence of TCO-NHS ester (8 arms × 4 AEA × 1.2 eq; 
11.6 mg, 4.4×10-2 mmol) in 27 mL DMF at 60°C for 16 
hours. Small molecular weight impurities were 
removed by dialysis in 5% DMSO and large molecular 
weight impurities using PTFE syringe filters (0.1 µm, 
GE Healthcare). Purified TCO-functionalised star 
polymer 9 (p(TCO-AEA-co-OEGA-co-[Gd3+]VDMD)) 
was stored in solution at 4°C and analysed by 1H 
NMR (D2O) and DLS. 
Tz-PEG7-DOTA (10; 1 eq; 15 µg, 12.5 nmol) was 
added to [177Lu]LuCl3 (~95 MBq) in 100 µL 0.25M 
NH4OAc buffer in chelex water (pH 5.5) and mixed 
for 60 minutes at 37°C. TCO-functionalised star 
polymer 9 (8 arms × 4 TCO × 1.5 eq; 52.6 µg, 0.6 nmol) 
in 45 µL was added and the mixture was allowed to 
react for 30 minutes at 37°C. Purified radiolabelled 
star polymer 11 (p([177Lu]Lu-DPAEA-co-OEGA-co- 
[Gd3+]VDMD)) was obtained by centrifugal filtration 
(Amicon Ultra-4, 50k) using saline. Radiochemical 
purity was measured by iTLC using 50% ethanol as 
mobile phase. 
Cell Culture 
CT26 colon cancer cells were cultured in Roswell 
Park Memorial Institute (RPMI)-1640 growth 
medium, supplemented with 10% fetal calf serum 
(FCS). BxPC3 pancreatic cancer cells were cultured in 
RPMI-1640 growth medium, supplemented with 10% 
FCS and 2 mM L-glutamine. Both cell culture media 
were supplemented with 100 units mL−1 penicillin 
and streptomycin. 
Tumour Models 
All animals were treated according to the 
guidelines approved by the Research Animal 
Resource Center and Institutional Animal Care and 
Use Committee at Memorial Sloan Kettering Cancer 
Center. Six-to-eight week old female BALB/c or 
athymic nude mice (Charles River Laboratories, New 
York, USA) were injected subcutaneously with CT26 
cells (1 × 105 cells) or BxPC3 cells (5 × 106 cells) in 150 
µL 1:1 growth media/Matrigel® (BD Biosciences, San 
Jose, CA), respectively. Cells were injected using a 
sterile syringe equipped with a 28-gauge needle in 
either right flank. Mice were allowed to acclimatise to 
laboratory conditions for 1 week prior to injection of 
the tumour cells and were housed in type II 
polycarbonate cages at 22 °C (60% relative humidity) 
in a 12 h light - 12 h dark cycle, while providing a 
sterilised standard laboratory diet and sterile water ad 
libitum. Positron emission tomography (PET) imaging 
and biodistribution studies were performed within 
2-5 weeks after injection, when tumour volumes 
reached 100-250 mm3. Tumour volume V was 
estimated by Vernier calliper measurements of the 
longest tumour axis a and its perpendicular axis b, 
using the formula V = (4π/3) × (a/2)2 × (b/2). 
At defined time points prior to imaging or ex vivo 





biodistribution studies, mice were injected with 15 µg 
p([89Zr]Zr-DFO-AEA-co-OEGA-co-[Gd3+]VDMD) star 
polymer 8 (10 MBq, MA = 64 GBq/µmol), or 15 µg 
p([177Lu]Lu-DPAEA-co-OEGA-co-[Gd3+]VDMD) star 
polymer 11 (0.8 MBq, MA = 5 GBq/µmol) in 130-150 
µL saline (0.9% NaCl). All compounds were 
administered by tail vein injection. 
1H Relaxivity and Magnetic Resonance Imaging 
(MRI) 
A 1H nuclear magnetic resonance dispersion 
(NMRD) profile was obtained at 310 K over a 
continuum of magnetic fields from 0.24 mT to 0.94 T 
(0.01 – 40 MHz) using a Spinmaster FFC-2000 (fast 
field cycling) NMR relaxometer (Stelar, Mede PV, 
Italy). An aqueous suspension of the Gd3+-labelled 
nanostars (1 mL) was placed in a 10 mm NMR tube 
and equilibrated at the set temperature for 15 minutes 
prior to conducting any experiments. The recycle 
delay was set to ≥ 5 T1, and the signal was averaged 
over four scans for all measurements. Relaxivities 
were calculated by subtracting the diamagnetic 
contribution to the relaxation rates (i.e. relaxation 
rates of water without the paramagnetic contrast 
agent) from the measured relaxation rates, and 
normalising the values to the Gd3+ concentration. The 
nonlinear least-squares fitting of the 1H NMRD data 
was performed using the Levenberg-Marquardt 
algorithm implemented in Origin 2018 software 
(Originlab Corporation, Massachusetts, USA). 
For 3 T T1-weighted MRI imaging and relaxivity 
measurements, a dilution series of Gd3+-labelled 
nanostars in HEPES buffer in 5 mm NMR tubes (500 
µL) or anaesthetised mice (n = 3; oxygen gas mixture 
with 1.5-2% isofluorane (Baxter Healthcare, Deerfield, 
USA)), injected with 3 mg or 10 mg of nanostar 6 
(p(BAEA-co-OEGA-co-VDM)), were positioned in a 
1H transmit/receive volume coil with quadrature 
detection at the isocentre of a 3 T BioSpec MRI scanner 
(Bruker). For the phantom studies, T1-weighted MRI 
images were acquired using a gradient echo sequence 
(TR = 22.6 ms, TE = 3.6 ms, 30 mm × 10 mm field of 
view (96 × 32 resolution), 2 mm slice thickness, 10 
averages) at a 21-degree pulse angle. For the in vivo 
studies, T1-weighted MRI images were acquired using 
a gradient echo sequence (TR = 21.955 ms, TE = 3.003 
ms, 30 mm × 30 mm field of view (96 × 96 resolution), 
2 mm slice thickness, 30 averages) at a 15-degree pulse 
angle. Relaxivity of the nanostars at 3 T was calculated 
from water proton T1 measurements at varying 
nanostar concentrations (0 mg/mL, 0.125 mg/mL, 
0.25 mg/mL, 0.5 mg/mL, 1 mg/mL). T1 values of 
these solutions were acquired with a Look-Locker 
T1-map sequence across an axial 2 mm slice with a 20 
mm × 20 mm field of view (160 × 160 resolution), 10 
ms echo time, 4000 ms dummy duration, 1 average 
and repetition times of 2000, 1500, 1000, 700, 500, 300, 
150 and 50 ms. T1-maps were generated in Paravision 
6.0.1 (Bruker), regions of interest (ROI) were drawn 
around the areas corresponding to each individual 
sample and ROIs were integrated to calculate T1. 
These T1 values were subsequently used to calculate 
relaxivity (r1). For in vivo imaging studies, MR image 
volumes were co-registered with the subsequent 
PET/CT scans of each mouse using Elastix 
deformable image registration within open source 3D 
Slicer software (v4.8.1). T1-weighted contrast 3 days 
after injection of the nanostars was compared to 
baseline pre-injection MR images. 
Relaxivity of the Gd3+-labelled nanostars 
(5.95×10-8 mol Gd3+) at 7 T was compared with the 
relaxivity of Gadovist in 5 mm NMR tubes (550 µL), 
positioned in a 40 mm two channel 1H/19F volume 
coil at the isocentre of a simultaneous PET/MRI 
system (Bruker 7 T Clinscan interfaced with a Siemens 
Spectrometer running Numaris/4 VB17 with a PET 
ring positioned at the isocenter of the magnet 
consisting of three rings of 16 crystal blocks), while 
acquiring T1-weighted images using a 3D VIBE 
sequence (TR=12ms, TE=0.93ms, in-plane 
resolution=0.312mm) at 5 different flip angles.  
Positron Emission Tomography (PET) Imaging 
Mice (n = 4-5 per timepoint) were anesthetised 
5-10 minutes prior to scanning via inhalation of a 
1.5-2% isofluorane in oxygen gas mixture. PET images 
were acquired on an Inveon small-animal 
micro-PET/CT scanner (Siemens Medical Solutions, 
Knoxville, USA) or a Focus 120 small-animal PET 
scanner (Siemens Medical Solutions, Knoxville, USA) 
under 1.5-2% isofluorane/oxygen anaesthesia using a 
dedicated quadruple animal scanning platform for 
simultaneous scanning. PET data were recorded using 
a minimum of 15 million coincident events (~ 15 
minutes) with an energy window of 350-650 keV and 
a coincidence-timing window of 6 ns. Data were 
sorted into 2-dimensional histograms by Fourier 
rebinning, and transverse images were reconstructed 
by filtered back-projection or 2-dimensional ordered 
subset expectation maximisation (2D-OSEM) into a 
128 x 128 matrix. The image data were normalised to 
correct for nonuniformity of response of the PET, 
dead-time count losses, positron branching ratio, and 
physical decay to the time of injection, but no 
attenuation, scatter, or partial-volume averaging 
correction was applied. Individual image volumes 
were constructed using the cropping function of the 
Inveon Research Workspace software (Siemens 
Medical Solutions, Knoxville, USA). Activity 
concentrations (%ID/g) were obtained by conversion 





of the counting rates in the reconstructed images 
using a system calibration factor, derived from a 
mouse-sized water-equivalent phantom containing 
89Zr. Further image processing was performed using 
3D Slicer software (v4.8.1). Intensity scales for both 
the high EPR (CT26) and low EPR tumour (BxPC3) 
models were adjusted to an apparently similar liver 
and spleen uptake for both models, warranting the 
fair comparison of PET data obtained from mice with 
two different backgrounds (i.e. BALB/c and athymic 
nude mice). Three-dimensional volumes of interest 
(VOIs) were defined through semi-automatic 
segmentation techniques and activity concentrations 
were quantified by selecting the maximal intensity 
voxel per VOI.  
Ex Vivo Biodistribution 
Mice (n = 4-5 per timepoint) were euthanised via 
CO2 asphyxiation and organs of interest (including 
tumour tissue) were removed, rinsed in water and 
dried in air for several minutes, before tissues were 
weighed and counted using a gamma counter. 
Measured counts were converted into radioactivity 
units using a calibration curve obtained from known 
standards for 89Zr or 177Lu. The injected dose per 
tissue mass (%ID/g) was calculated after background- 
and decay-correction to the time of radioligand 
injection. 
Dosimetry and Therapy Studies 
Dosimetry studies were performed according to 
procedures described previously [51]. Briefly, the 
time-integrated activity coefficients (i.e. residence 
times) per organ were calculated by trapezoidal 
integration of the time-activity curves for each organ, 
based on biodistribution data for the 
p([177Lu]Lu-DPAEA-co-OEGA-co-[Gd3+]VDMD) star 
polymer (11). Clearance of activity following the last 
measured time point was assumed to be due to 
radioactive decay only. Resulting organ 
time-integrated activity coefficients were entered into 
OLINDA software (v2.0) to estimate mean organ-level 
absorbed doses (Gy/MBq) for the ICRP89 adult male 
model. These methods assume that the standardised 
uptake values are invariant between organs in mice 
and humans [56].  
Tissue absorbed dose estimates for mice assume 
self-absorbed fractions of 1 for weakly-penetrating 
raditions and 0 for photons. Optimal mouse therapy 
doses were estimated from maximum tolerated doses 
for all organs. BALB/c mice with CT26 colon cancer 
isografts were randomized in five cohorts (n = 8 per 
cohort) with approximately equal average tumour 
volumes. To minimize bias due to outliers, the two 
mice with the smallest and largest tumours were 
excluded from each therapy cohort (Figure S17). One 
day after randomization, mice were injected with 1.5 
MBq, 3.7 MBq or 7.4 MBq of p([177Lu]Lu-DPAEA-co- 
OEGA-co-[Gd3+]VDMD) star polymer (11; 23 µg per 
mouse). Mice in the two control groups were injected 
either with vehicle (0.9% sterile saline) or 
non-radioactive nanostar 6 (p(BAEA-co-OEGA-co- 
VDM); 23 µg per mouse). Tumour volumes and body 
weights were measured twice per week until tumour 
volume V > 2000 mm3.  
Toxicity studies 
Mice were monitored for outward signs of 
toxicity, including lethargy and loss of appetite. Blood 
samples (50–100 µL, n = 3 per cohort) were collected 
retroorbitally twice per week and analysed using an 
Hemavet 950 (Drew Scientific). Potential 
haematological toxicity was assessed by comparing 
red blood cell counts, haematocrit values, platelet 
counts and white blood cell counts between cohorts 
and with baseline measurements one day prior to 
injection. 
Statistical Analysis 
Data were compared using a two-tailed 
independent-samples t-test, for which equal variances 
were not assumed if Levene’s Test for Equality of 
Variances was significant. Cumulative survival was 
defined as the time in days after injection until 
euthanisation. Statistical tests and survival analyses 
were performed using SPSS Statistics software (v25, 
IBM, Armonk, USA) or RStudio Statistics 3.6.0 
software (RStudio Inc., Boston, USA) and were 
considered significant at the 95% confidence interval 
(P<0.05). 
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